211 related articles for article (PubMed ID: 36251168)
1. Causal effect of anxiety and depression status on the symptoms of gastroesophageal reflux disease and functional dyspepsia during proton pump inhibitor therapy.
Nakada K; Oshio A; Matsuhashi N; Iwakiri K; Kamiya T; Manabe N; Joh T; Higuchi K; Haruma K
Esophagus; 2023 Apr; 20(2):309-316. PubMed ID: 36251168
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitor monotherapy is effective to attenuate dyspepsia symptoms associated with gastroesophageal reflux disease: a multicenter prospective observational study.
Isshi K; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Ogawa M; Arihiro S; Haruma K; Nakada K
J Gastroenterol; 2019 Jun; 54(6):492-500. PubMed ID: 30673836
[TBL] [Abstract][Full Text] [Related]
3. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a simple and multifaceted instrument, GERD-TEST, for the clinical evaluation of gastroesophageal reflux and dyspeptic symptoms.
Nakada K; Matsuhashi N; Iwakiri K; Oshio A; Joh T; Higuchi K; Haruma K
World J Gastroenterol; 2017 Jul; 23(28):5216-5228. PubMed ID: 28811716
[TBL] [Abstract][Full Text] [Related]
5. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor.
Takeuchi T; Takahashi Y; Kawaguchi S; Ota K; Harada S; Kojima Y; Sakamoto H; Kuramoto T; Kojima K; Sanomura M; Hoshimoto M; Higashino T; Itabashi T; Takada K; Sakaguchi M; Tominaga K; Kusano M; Higuchi K
J Gastroenterol Hepatol; 2018 Mar; 33(3):623-630. PubMed ID: 28865098
[TBL] [Abstract][Full Text] [Related]
6. Effects of coexisting upper gastrointestinal symptoms on daily life and quality of life in patients with gastroesophageal reflux disease symptoms.
Isshi K; Furuhashi H; Koizumi A; Nakada K
Esophagus; 2021 Jul; 18(3):684-692. PubMed ID: 33389239
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of gastroesophageal reflux disease symptoms and effects of esomeprazole on the quality of life related to reflux and dyspepsia in patients on maintenance hemodialysis.
Namikoshi T; Harada K; Hatta H; Tokura T; Oshiro Y; Nishizaki T; Obata T; Mori M; Fueki T; Fujimoto S; Haruna Y; Kuwabara A; Yorimitsu D; Ihoriya C; Kadoya H; Itano S; Fujimoto Y; Komai N; Sasaki T; Kashihara N
Clin Exp Nephrol; 2016 Feb; 20(1):134-42. PubMed ID: 26026991
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: sustained response to PPI treatment of symptoms resembling functional dyspepsia and irritable bowel syndrome in patients suffering from an overlap with erosive gastro-oesophageal reflux disease.
Mönnikes H; Schwan T; van Rensburg C; Straszak A; Theek C; Sander P; Lühmann R
Aliment Pharmacol Ther; 2012 Jun; 35(11):1279-89. PubMed ID: 22486552
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for functional dyspepsia, erosive and non-erosive gastroesophageal reflux disease: A cross-sectional study.
Caballero-Mateos AM; López-Hidalgo JL; Torres-Parejo Ú; Hernández-González JM; Quintero-Fuentes MD; Caballero-Plasencia AM; Redondo-Cerezo E
Gastroenterol Hepatol; 2023; 46(7):542-552. PubMed ID: 36584749
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Kusano M; Shimoyama Y; Kawamura O; Maeda M; Kuribayashi S; Nagoshi A; Zai H; Moki F; Horikoshi T; Toki M; Sugimoto S; Mori M
Dig Dis Sci; 2007 Jul; 52(7):1673-7. PubMed ID: 17385034
[TBL] [Abstract][Full Text] [Related]
12. Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community.
Pleyer C; Bittner H; Locke GR; Choung RS; Zinsmeister AR; Schleck CD; Herrick LM; Talley NJ
Neurogastroenterol Motil; 2014 Aug; 26(8):1163-71. PubMed ID: 24916517
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of individual symptoms of gastroesophageal reflux disease co-existing functional dyspepsia on patients' daily lives: A prospective, observational study.
Nakada T; Isshi K; Matsuhashi N; Iwakiri K; Kamiya T; Manabe N; Higuchi K; Joh T; Oshio A; Ogawa M; Hokari A; Saruta M; Haruma K; Nakada K
JGH Open; 2022 Dec; 6(12):886-893. PubMed ID: 36514504
[TBL] [Abstract][Full Text] [Related]
14. Clinical and psychological characteristics in gastroesophageal reflux disease patients overlapping with laryngopharyngeal reflux symptoms.
Wong MW; Bair MJ; Chang WC; Hsu CS; Hung JS; Liu TT; Yi CH; Lei WY; Vaezi MF; Gyawali CP; Chen CL
J Gastroenterol Hepatol; 2019 Oct; 34(10):1720-1726. PubMed ID: 30851003
[TBL] [Abstract][Full Text] [Related]
15. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
[TBL] [Abstract][Full Text] [Related]
16. Relevance of Excessive Air Swallowing in GERD Patients With Concomitant Functional Dyspepsia and Poor Response to PPI Therapy.
Ribolsi M; Savarino E; Frazzoni M; Cicala M
J Clin Gastroenterol; 2023 May-Jun 01; 57(5):466-471. PubMed ID: 35648971
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic strategy for the patients with coexisting gastroesophageal reflux disease and postprandial distress syndrome of functional dyspepsia.
Isshi K; Furuhashi H; Nakada K
JGH Open; 2020 Aug; 4(4):582-588. PubMed ID: 32782942
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
19. The early therapeutic response at 2 weeks is a crucial predictor of proton pump inhibitor-refractory gastroesophageal reflux disease.
Ogawa M; Arihiro S; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Isshi K; Nakada T; Hokari A; Saruta M; Oshio A; Haruma K; Nakada K
Esophagus; 2021 Apr; 18(2):398-406. PubMed ID: 33136239
[TBL] [Abstract][Full Text] [Related]
20. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
